Dendritic Cell (DC)/Myeloma Fusions in Combination With Nivolumab in Patients With Relapsed Multiple Myeloma

Study Overview

This research study is studying a cancer vaccine called Dendritic Cell/MM Fusion vaccine (DC/MM vaccine) in combination with nivolumab, as a possible treatment for multiple myeloma (MM).

The drugs involved in this study are:

  • Dendritic Cell/MM Fusion vaccine (DC/MM vaccine)
  • Nivolumab, an immunotherapy drug

Study Description

A Phase II Trial of Vaccination with Dendritic Cell (DC)/Myeloma Fusions in Combination with Nivolumab in Patients with Relapsed Multiple Myeloma

  • ClinicalTrials.gov Identifier: NCT03782064
  • Protocol Number: 18-280
  • Principal Investigator: Myrna Nahas

Recruitment Status

Open

Contact the research team to learn more about this study.

Fields marked with asterisk (*) are required

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

If you need assistance finding a study or if you have any questions, call us at 617-667-7000